GlassScriptPhysician profile
Son Nguyen
NPI 1194025866
$4,297.80
in general payments reported to CMS, 2019-2025
26 companies · $1,538 in 2025
The $1,538 reported for 2025 was more than what 87% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $74.13 · 2022: $554 · 2023: $1,114 · 2024: $1,017 · 2025: $1,538.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,042 · Education: $627.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,042.44 |
| Education | $626.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $1,086.60 | 2022-2025 | Xtandi, Padcev |
| Emd Serono, INC. | $457.90 | 2023-2025 | Bavencio |
| Sobi, INC | $430.10 | 2022-2025 | |
| Janssen Biotech, INC. | $417.44 | 2021-2025 | Erleada, Talvey, Tecvayli |
| Novartis Pharmaceuticals Corporation | $272.21 | 2022-2025 | |
| Pfizer INC. | $265.30 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $257.50 | 2023-2024 | |
| Eisai INC. | $152.40 | 2023-2025 | |
| Amgen INC. | $145.31 | 2022-2023 | Nplate, Xgeva |
| Madrigal Pharmaceuticals | $142.72 | 2025 | Rezdiffra |
| Seagen INC. | $93.00 | 2025 | |
| Caris Mpi, INC. | $88.22 | 2025 | Mi Cancer Seek |
| Exelixis INC. | $63.96 | 2024-2025 | Cabometyx |
| Dendreon Pharmaceuticals LLC | $55.81 | 2022-2025 | Provenge |
| Sumitomo Pharma America, INC. | $53.63 | 2023-2025 | Orgovyx |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $50.79 | 2025 | Datroway |
| Incyte Corporation | $50.36 | 2023 | Jakafi |
| Merck Sharp & Dohme LLC | $45.15 | 2025 | Keytruda, Welireg |
| Puma Biotechnology, INC. | $29.96 | 2023 | |
| Glaxosmithkline, LLC. | $23.24 | 2021 | |
| Dova Pharmaceuticals | $21.74 | 2021 | |
| Blueprint Medicines Corporation | $20.80 | 2023 | Ayvakit |
| Alexion Pharmaceuticals, INC. | $20.46 | 2023 | Ultomiris |
| Celgene Corporation | $19.66 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $18.94 | 2023 | Lynparza |
| Tolmar, INC. | $14.60 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Son Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.